No connection

Search Results

PASW vs RECT

PASW
Ping An Biomedical Co., Ltd.
BEARISH
Price
$0.17
Market Cap
$20.7M
Sector
Consumer Cyclical
AI Confidence
90%
RECT
Rectitude Holdings Ltd
BULLISH
Price
$1.62
Market Cap
$23.5M
Sector
Consumer Cyclical
AI Confidence
75%

Valuation

P/E Ratio
PASW
--
RECT
8.1
Forward P/E
PASW
--
RECT
--
P/B Ratio
PASW
0.51
RECT
1.1
P/S Ratio
PASW
0.61
RECT
0.51
EV/EBITDA
PASW
-0.91
RECT
6.31

Profitability

Gross Margin
PASW
2.78%
RECT
31.94%
Operating Margin
PASW
-69.64%
RECT
11.19%
Profit Margin
PASW
-37.57%
RECT
8.13%
ROE
PASW
-67.43%
RECT
14.9%
ROA
PASW
-14.67%
RECT
4.97%

Growth

Revenue Growth
PASW
-62.0%
RECT
10.8%
Earnings Growth
PASW
--
RECT
125.0%

Financial Health

Debt/Equity
PASW
0.23
RECT
0.35
Current Ratio
PASW
2.76
RECT
2.25
Quick Ratio
PASW
0.8
RECT
1.59

Dividends

Dividend Yield
PASW
--
RECT
--
Payout Ratio
PASW
0.0%
RECT
0.0%

AI Verdict

PASW BEARISH

PASW presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 5/9 but catastrophic operational decay. While the balance sheet remains relatively clean with low debt and a healthy current ratio, the company has suffered a massive 62% year-over-year revenue collapse and negative profit margins. The 95% decline in share price over the last year reflects a fundamental breakdown in the business model, which is not offset by the low Price-to-Book ratio of 0.51.

Strengths
Low Debt/Equity ratio (0.23) indicating minimal leverage
Strong Current Ratio (2.76) suggesting short-term liquidity
Trading significantly below book value (P/B 0.51)
Risks
Severe revenue contraction (-62% YoY)
Extremely thin gross margins (2.78%) leaving no room for error
Deeply negative operating margins (-69.64%)
RECT BULLISH

RECT exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a conservative Debt/Equity ratio of 0.35. The stock is significantly undervalued, trading at $1.62 against a Graham Number of $2.57 and an intrinsic value of $5.90. Despite a devastating one-year price decline of 59.4%, explosive earnings growth (125% YoY) and a recent short-term price recovery suggest a potential value reversal. The company significantly outperforms sector averages in profitability and leverage, though it remains a high-risk micro-cap.

Strengths
Strong Piotroski F-Score (7/9) indicating high financial health
Explosive earnings growth (125% YoY and 135.8% Q/Q)
Deeply undervalued relative to Graham Number ($2.57) and Intrinsic Value ($5.90)
Risks
Severe long-term price depreciation (-59.4% over 1 year)
Micro-cap liquidity and volatility risk ($0.02B Market Cap)
Low insider sentiment (40/100) suggesting lack of internal conviction

Compare Another Pair

PASW vs RECT: Head-to-Head Comparison

This page compares Ping An Biomedical Co., Ltd. (PASW) and Rectitude Holdings Ltd (RECT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile